Activation of LXRα transactivates hepatic lipogenic genes and LXRα is found to be upregulated in the case of non-alcoholic fatty liver disease (NAFLD); thus, LXR antagonists might be useful for NASH therapy [121,122]. This evidence concerns the gene NR1H3 and metabolic dysfunction-associated steatohepatitis.